Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,013 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.
Berg DD, Patel SM, Haller PM, et al. · Circulation · 2025Meta-Analysis, Randomized Controlled Trial
- The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Voors AA, Angermann CE, Teerlink JR, et al. · Nat Med · 2022Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F, Ferreira JP, Pocock SJ, et al. · Lancet · 2020Meta-Analysis, Research Support, Non-U.S. Gov't
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Solomon SD, McMurray JJV, Claggett B, et al. · N Engl J Med · 2022Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Packer M, Anker SD, Butler J, et al. · N Engl J Med · 2020Multicenter Study, Randomized Controlled Trial
- Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis.
van Essen BJ, Ceelen DCH, Ouwerkerk W, et al. · J Am Coll Cardiol · 2025Systematic Review, Network Meta-Analysis
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Lancet · 2022Systematic Review, Meta-Analysis
- Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis.
Usman MS, Bhatt DL, Hameed I, et al. · Lancet Diabetes Endocrinol · 2024Systematic Review, Meta-Analysis
- SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.
Neuen BL, Fletcher RA, Anker SD, et al. · JAMA · 2026Meta-Analysis
- Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Shi Q, Nong K, Vandvik PO, et al. · BMJ · 2023Systematic Review, Network Meta-Analysis
- Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials.
Carvalho PEP, Veiga TMA, Simões E Silva AC, et al. · Clin Res Cardiol · 2023Comparative Study, Meta-Analysis
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
McMurray JJV, Solomon SD, Inzucchi SE, et al. · N Engl J Med · 2019Clinical Trial, Phase III, Multicenter Study
- Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis.
Aldafas R, Crabtree T, Alkharaiji M, et al. · Age Ageing · 2024Meta-Analysis, Systematic Review
- The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.
Nassif ME, Windsor SL, Borlaug BA, et al. · Nat Med · 2021Multicenter Study, Randomized Controlled Trial
- SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.
Vaduganathan M, Docherty KF, Claggett BL, et al. · Lancet · 2022Meta-Analysis
- Diuretic Potentiation Strategies in Acute Heart Failure.
Siddiqi TJ, Packer M, Ezekowitz JA, et al. · JACC Heart Fail · 2025Systematic Review, Research Support, Non-U.S. Gov't
- Empagliflozin after Acute Myocardial Infarction.
Butler J, Jones WS, Udell JA, et al. · N Engl J Med · 2024Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis.
Ali AE, Mazroua MS, ElSaban M, et al. · Glob Heart · 2023Meta-Analysis, Systematic Review
- Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
Kongmalai T, Hadnorntun P, Leelahavarong P, et al. · Front Endocrinol (Lausanne) · 2023Systematic Review, Research Support, Non-U.S. Gov't
- Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
Hamid AK, Tayem AA, Al-Aish ST, et al. · Ther Adv Cardiovasc Dis · 2024Systematic Review, Meta-Analysis
- SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis.
Banerjee M, Pal R, Nair K, et al. · Indian Heart J · 2023Meta-Analysis, Systematic Review
- Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials.
Wanner C, Iliev H, Duarte N, et al. · Adv Ther · 2024Meta-Analysis, Research Support, Non-U.S. Gov't
- Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure.
James S, Erlinge D, Storey RF, et al. · NEJM Evid · 2024Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs.
Gao H, Wei Q, Zou A, et al. · Front Endocrinol (Lausanne) · 2025Network Meta-Analysis, Systematic Review
- Tricuspid-Valve Intervention in Heart Failure.
Hausleiter J, Stocker TJ, Geisler T, et al. · N Engl J Med · 2026Randomized Controlled Trial, Multicenter Study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.